(A) Study design. (B) Gross image and H&E staining of Akt/Fak mouse livers. (C) Liver weight of Akt/Fak mice at 18–19 weeks post-injection. (D) Immunohistochemistry of CK19, Ki-67, and YAP in Akt/Fak mice. (E) Western blot analysis of FVB mice and Akt/Fak mouse model liver tissues. (F) YAP and NOTCH signaling activation at the transcriptional level, as assessed by qPCR. Tukey–Kramer test: at least P < 0.05; a, vs FVB WT; b, vs Akt.